BRPI0607088A2 - derivados de tetrahidrofurano heterocìclico tetracìclico como inibidores de 5ht2 no tratamento de distúrbios cns - Google Patents
derivados de tetrahidrofurano heterocìclico tetracìclico como inibidores de 5ht2 no tratamento de distúrbios cnsInfo
- Publication number
- BRPI0607088A2 BRPI0607088A2 BRPI0607088-4A BRPI0607088A BRPI0607088A2 BR PI0607088 A2 BRPI0607088 A2 BR PI0607088A2 BR PI0607088 A BRPI0607088 A BR PI0607088A BR PI0607088 A2 BRPI0607088 A2 BR PI0607088A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- tetrahydrofuran derivatives
- inhibitors
- receptors
- tetracyclic heterocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
DERIVADOS DE TETRAHIDROFURANO HETEROCìCLICO TETRACICLICO COMO INIBIDORES DE 5HT2 NO TRATAMENTO DE DISTúRBIOS CNS. A presente invenção refere-se a novos derivados de tetrahidrofurano heterocíclico tetracíclico substituidos com afinidades de ligação por receptores de serotonina, em particular receptores 5-HT2A e 5-HT2ç e por receptores de dopamina, em particular receptores de dopamina D2 e com propriedades de inibição da recaptação de norepinefrina, composições farmacêuticas compreendendo os compostos de acordo com a invenção, o uso dos mesmos como um medicamento, em particular para a prevenção e/ou tratamento de uma série de distúrbios psiquiátricos e neurológicos, em particular determinados distúrbios psicóticos, cardiovasculares e gastrocinéticos e processos para sua produção. Os compostos de acordo com a invenção podem ser representados pela Fórmula geral (1): e compreendem também os sais de adição de base ou ácido farmaceuticamente aceitáveis dos mesmos, as formas estereoquimicamente isoméricas dos mesmos, a forma de N-óxido dos mesmos e pró-fármacos dos mesmos, em que todos os substituintes são definido conforme na reivindicação 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05100547 | 2005-01-27 | ||
| PCT/EP2006/050444 WO2006079637A1 (en) | 2005-01-27 | 2006-01-25 | Heterocyclic tetracyclic tetrahydrofuran derivatives as 5ht2 inhibitors in the treatment of cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0607088A2 true BRPI0607088A2 (pt) | 2009-08-04 |
Family
ID=34938591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0607088-4A BRPI0607088A2 (pt) | 2005-01-27 | 2006-01-25 | derivados de tetrahidrofurano heterocìclico tetracìclico como inibidores de 5ht2 no tratamento de distúrbios cns |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7915249B2 (pt) |
| EP (1) | EP1846415B1 (pt) |
| JP (1) | JP4937141B2 (pt) |
| KR (1) | KR101332218B1 (pt) |
| CN (1) | CN101107254B (pt) |
| AU (1) | AU2006209397B2 (pt) |
| BR (1) | BRPI0607088A2 (pt) |
| CA (1) | CA2595170C (pt) |
| EA (1) | EA013595B1 (pt) |
| ES (1) | ES2391780T3 (pt) |
| MX (1) | MX2007009092A (pt) |
| NZ (1) | NZ556272A (pt) |
| WO (1) | WO2006079637A1 (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200523253A (en) | 2003-07-22 | 2005-07-16 | Arena Pharm Inc | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| PE20061130A1 (es) | 2004-11-19 | 2007-01-05 | Arena Pharm Inc | Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a |
| WO2007136703A1 (en) | 2006-05-18 | 2007-11-29 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| NZ594353A (en) | 2006-05-18 | 2013-02-22 | Arena Pharm Inc | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor |
| EP2027119A2 (en) | 2006-05-18 | 2009-02-25 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| US9567327B2 (en) | 2007-08-15 | 2017-02-14 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
| BRPI0908098A2 (pt) * | 2008-02-19 | 2015-08-18 | Adolor Corp | Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2 |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| CN104784173B (zh) | 2008-10-28 | 2019-07-26 | 艾尼纳制药公司 | 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物 |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| US8980891B2 (en) | 2009-12-18 | 2015-03-17 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| JP2018516992A (ja) | 2015-06-12 | 2018-06-28 | アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体 |
| AU2016291673A1 (en) | 2015-07-15 | 2018-01-25 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
| BR112021024870A2 (pt) * | 2019-06-12 | 2022-01-18 | Nouryon Chemicals Int Bv | Método para isolar ácido carboxílico de uma corrente lateral aquosa de um processo de produção de peróxido orgânico |
| EP3983370B1 (en) | 2019-06-12 | 2023-08-02 | Nouryon Chemicals International B.V. | Process for the production of diacyl peroxides |
| US11976035B2 (en) | 2019-06-12 | 2024-05-07 | Nouryon Chemicals International B.V. | Process for the production of diacyl peroxides |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH615928A5 (pt) | 1975-06-18 | 1980-02-29 | Sandoz Ag | |
| CS200271B1 (cs) | 1979-02-08 | 1980-09-15 | Miroslav Rajsner | Derivát 4,5-dihydrothieno (2,3-b)-l-benzothiepinu a jeho eoli |
| CS217949B1 (cs) | 1981-08-14 | 1983-01-28 | Miroslav Protiva | Derivát 4,5-dihydrothieno(2,3-b)-1-benzothiepinu a jeho soli |
| PL158223B1 (en) | 1989-06-09 | 1992-08-31 | Method for mnufacturing 4-(1-methyl-4-pirperidilidene)-9,10-dihydro--benso(4,5) cyclohepta (1,2) thiophen-10-on | |
| HU221608B (hu) * | 1996-04-12 | 2002-11-28 | Janssen Pharmaceutica N.V. | Izoxazolidinszármazékok |
| JP3199751B2 (ja) * | 1996-04-12 | 2001-08-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換された四環式テトラヒドロフラン誘導体 |
| UA52778C2 (uk) * | 1997-10-10 | 2003-01-15 | Янссен Фармацевтика Н.В. | Галогенозаміщені тетрациклічні похідні тетрагідрофурану, спосіб їх отримання та композиція на їх основі |
| UA79248C2 (en) | 2001-11-09 | 2007-06-11 | Janssen Pharmaceutica Nv | Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives |
| JP4516752B2 (ja) | 2001-12-07 | 2010-08-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | トランス−縮合３，３ａ，８，１２ｂ−テトラヒドロ−２Ｈ−ジベンゾ［３，４：６，７］シクロヘプタ［１，２−ｂ］フラン誘導体の製造法 |
| RU2401257C2 (ru) * | 2004-12-07 | 2010-10-10 | Янссен Фармацевтика Н.В. | Новые замещенные тетрациклические производные тетрагидрофурана, пирролидина и тетрагидротиофена |
-
2006
- 2006-01-25 WO PCT/EP2006/050444 patent/WO2006079637A1/en active Application Filing
- 2006-01-25 KR KR1020077019160A patent/KR101332218B1/ko not_active IP Right Cessation
- 2006-01-25 MX MX2007009092A patent/MX2007009092A/es active IP Right Grant
- 2006-01-25 CA CA2595170A patent/CA2595170C/en not_active Expired - Fee Related
- 2006-01-25 ES ES06704282T patent/ES2391780T3/es active Active
- 2006-01-25 BR BRPI0607088-4A patent/BRPI0607088A2/pt not_active IP Right Cessation
- 2006-01-25 EP EP06704282A patent/EP1846415B1/en active Active
- 2006-01-25 JP JP2007552640A patent/JP4937141B2/ja not_active Expired - Fee Related
- 2006-01-25 NZ NZ556272A patent/NZ556272A/en not_active IP Right Cessation
- 2006-01-25 EA EA200701583A patent/EA013595B1/ru not_active IP Right Cessation
- 2006-01-25 US US11/814,432 patent/US7915249B2/en not_active Expired - Fee Related
- 2006-01-25 AU AU2006209397A patent/AU2006209397B2/en not_active Ceased
- 2006-01-25 CN CN2006800032542A patent/CN101107254B/zh not_active Expired - Fee Related
-
2011
- 2011-02-16 US US13/028,596 patent/US8404729B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101107254A (zh) | 2008-01-16 |
| JP2008528548A (ja) | 2008-07-31 |
| JP4937141B2 (ja) | 2012-05-23 |
| EP1846415A1 (en) | 2007-10-24 |
| KR20070098938A (ko) | 2007-10-05 |
| WO2006079637A1 (en) | 2006-08-03 |
| US7915249B2 (en) | 2011-03-29 |
| CA2595170C (en) | 2014-08-05 |
| ES2391780T3 (es) | 2012-11-29 |
| NZ556272A (en) | 2009-12-24 |
| CN101107254B (zh) | 2010-12-08 |
| EA013595B1 (ru) | 2010-06-30 |
| US20110144094A1 (en) | 2011-06-16 |
| WO2006079637A8 (en) | 2007-08-16 |
| US20080108599A1 (en) | 2008-05-08 |
| EP1846415B1 (en) | 2012-08-01 |
| AU2006209397A1 (en) | 2006-08-03 |
| KR101332218B1 (ko) | 2013-11-25 |
| EA200701583A1 (ru) | 2008-04-28 |
| AU2006209397B2 (en) | 2011-04-07 |
| MX2007009092A (es) | 2007-09-12 |
| CA2595170A1 (en) | 2006-08-03 |
| US8404729B2 (en) | 2013-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0607088A2 (pt) | derivados de tetrahidrofurano heterocìclico tetracìclico como inibidores de 5ht2 no tratamento de distúrbios cns | |
| TW200716120A (en) | Pyrazolo-pyrimidine derivatives as mGluR2 antagonists | |
| GEP20125566B (en) | Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | |
| NO20074592L (no) | Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister | |
| BRPI0515081A (pt) | derivados de fenilaminopirimidina como inibidores de bcr-abl cinase | |
| DK1856090T3 (da) | Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser | |
| TNSN08405A1 (en) | Cyclohexylpyrazole - lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
| BRPI0817242A8 (pt) | compostos derivados de 1,1,1-trifluoro-2-hidroxi-3-fenilpropano, processo para a sua manufatura e composições farmacêuticas que os contêm | |
| BRPI0510453A (pt) | composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central | |
| ECSP088405A (es) | Nuevos derivados de pirimidina y su uso en terapia, así como el uso de derivados de pirimidina en la fabricación de un medicamento para la prevención y/o tratamiento de la enfermedad de alzheimer | |
| WO2009013212A3 (en) | Dual modulators of 5-ht2a and d3 receptors | |
| MX2009010505A (es) | Derivados de piridina y pirimidina como antagonistas de mglur2. | |
| MX2007010400A (es) | Nuevas sales de derivados de hexahidrofenantridina sustituida con 6-heterociclilo. | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| TW200612899A (en) | Novel tetracyclic tetrahydrofuran derivatives | |
| UA98772C2 (ru) | Производные циклопропиламина как модуляторы н3-гистаминового рецептора | |
| CY1111460T1 (el) | Μεθανοσουλφονικη 4-[(3-φθοροφαινοξυ) φαινυλο-μεθυλο] πιπεριδινη: χρησεις, διεργασια συνθεσης και φαρμακευτικες συνθεσεις | |
| BRPI0606881A2 (pt) | composto derivado de dihidroimidazotiazol, composição farmacêutica, seu uso e processo para a sua produção | |
| WO2009118765A8 (en) | Novel monoamine re-uptake inhibitor | |
| WO2006061392A3 (en) | Substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives | |
| DE602005016836D1 (de) | Chotischer und anxiolytischer aktivität | |
| DE602004007658D1 (de) | Indolderivate mit verbesserter antipsychotischer wirkung | |
| MX2010001195A (es) | Derivados de benzoil-peperidina como moduladores dobles de los receptores 5-ht2a y d3. | |
| BRPI0909737A2 (pt) | compostos de pirrolidinila, composição farmacêutica compreendendo os mesmos e usos dos mesmos | |
| MX2009002906A (es) | Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2498 DE 21-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |